Management ChangeJun 1, 2026, 10:03 AM

Revium Rx Appoints Igor Bluvstein as New CFO; Arie Gordashnikov Resigns

AI Summary

Revium Rx announced a change in its Chief Financial Officer position. Mr. Arie Gordashnikov resigned from his role as CFO of the company and its subsidiaries, effective May 27, 2026, with no stated disagreements. Concurrently, the Board of Directors appointed Mr. Igor Bluvstein as the new Chief Financial Officer, effective immediately. Mr. Bluvstein brings over 17 years of financial leadership experience from various sectors, including previous CFO roles at Argent BioPharma Ltd. and G Medical Innovations Holdings Ltd.

Key Highlights

Mr. Arie Gordashnikov resigned as Chief Financial Officer of Revium Rx and its subsidiaries, effective May 27, 2026.
His resignation was not due to any disagreement with the company's operations, policies, or practices.
Mr. Igor Bluvstein was appointed as the new Chief Financial Officer, effective May 27, 2026.
Mr. Bluvstein previously served as CFO of Argent BioPharma Ltd. (2024-2025) and G Medical Innovations Holdings Ltd. (2022-2024).
He has over 17 years of financial leadership experience across various industries.
Mr. Bluvstein will receive a monthly retainer of NIS17,000 plus VAT.

View SEC Filing

RVRC

Pharmaceutical Preparations

Revium Rx.

Price Impact